J&J Quality Issues, Hill Concerns Spill Over To Blacksmith's PediaCare
• By The Tan Sheet
The impact of McNeil Consumer Healthcare's quality control lapses extends to Blacksmith Brands, which becomes a congressional inquiry target after recalling PediaCare products manufactured at one of the Johnson & Johnson subsidiary's plants
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.
Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.